Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Xeragen
MEDITRIM T TABLETS MEDITRIM S SUSPENSION SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): MEDITRIM T TABLETS MEDITRIM S SUSPENSION COMPOSITION: Each tablet contains: Trimethoprim 80 mg Sulphamethoxazole 400 mg Nipastat (as preservative) 0,025% m/m Each 5 mL of suspension contains: Trimethoprim 40 mg Sulphamethoxazole 200 mg Nipastat (as preservative) 0,3% m/m (Contains alcohol 1,5% m/v) PHARMACOLOGICAL CLASSIFICATION: A 20.2 Antimicrobial (Chemotherapeutic) agents other than antibiotics. PHARMACOLOGICAL ACTION: MEDITRIM is a combination of trimethoprim and sulphamethoxazole and results in synergistic effects causing a bactericidal action. The action of co-trimoxazole is achieved by the sequential blocking of two enzymes essential in folinic acid synthesis in the organism. INDICATIONS: Infections caused by sensitive organisms of the upper and lower respiratory tract, the urinary tract and alimentary and genital tract in both sexes, and skin infections. CONTRA-INDICATIONS: Patients with known sulphonamide or trimethoprim hypersensitivity or who are suffering from porphyria. It should not be used in patients suffering from liver parenchymal damage, or a severe renal insufficiency. Co-trimoxazole should not be used during pregnancy or by lactating woman. Use of the substance in premature or new-born infants as well as during the first two months of life, is contra-indicated. Contra-indicated in the presence of vitamin B 12 and folic acid deficiency states. Should not be given to patients with megaloblastic anaemia or blood dyscrasia or in patients receiving anticonvulsant medicines. Trimethoprim should not usually be given to patients with serious haematological disorders and particularly not in megaloblastic anaemia secondary to folate depletion. WARNINGS: Erythema multiforme, toxic derma Read the complete document